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Background: Levetiracetam is a broad spectrum antiepileptic drug (AED) with proven efficacy when used as
adjunctive therapy against myoclonic seizures. We report two patients suffering from epilepsy with myoclonic-astatic
epilepsy (MAE) who experienced a paradoxical worsening of seizures after initiation of treatment with LEV, a finding
not previously described.
Case presentation: Patients included were enrolled in an ongoing large prospective study evaluating children
and adults with new onset epilepsy in Lebanon conducted at the American University of Beirut Medical
Center in association with the Lebanese Chapter of the International League against Epilepsy. Based on an
extensive evaluation, these patients were stratified into idiopathic partial, idiopathic generalized, symptomatic
partial or symptomatic generalized epilepsies. Whenever possible the electroclinical syndrome was identified
according to the ILAE classification of epilepsy syndromes. Patients were subsequently followed up on regular
intervals and were assessed for adverse events, and seizure recurrence.
MAE was diagnosed in five (1.6%) out of 307 consecutive children enrolled in this study. LEV was used as
adjunctive therapy in four of those children with two experiencing a substantial and dose related worsening
in the frequency of their myoclonic and atonic seizures.
Conclusion: LEV should be used with caution in children with MAE and an exacerbation of seizure frequency
temporally related to the introduction of LEV should alert the clinician to the possibility of a paradoxical
seizure exacerbation.
Keywords: Epilepsy, Electroclinical syndrome, Doose syndrome, Antiepileptic, Levetiracetam, MyoclonusBackground
Levetiracetam (LEV), one of the new generation antiepi-
leptic drugs (AEDs), is considered to be a broad spectrum
anticonvulsant with favorable safety and pharmacokinetic
profiles [1]. It is currently licensed in the USA as adjunct-
ive therapy for the treatment of partial onset seizures in
patients one month of age and older, myoclonic seizures
in patients 12 years and older diagnosed with juvenile
myoclonic epilepsy [2] and primarily generalized tonic-
clonic seizures in patients 6 years and older diagnosed
with an idiopathic generalized epilepsy [3].* Correspondence: ab29@aub.edu.lb
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unless otherwise stated.MAE, first described as an independent epilepsy syn-
drome by Doose [4] is included in the international classi-
fication of epilepsy syndromes as one of the cryptogenic/
symptomatic generalized epilepsies [5]. It was recently
renamed as epilepsy with myoclonic-atonic seizures and
classified as one of the childhood onset electroclinical syn-
dromes [6]. It is a generalized epilepsy, typically affecting
developmentally normal children with a mean age at onset
of 2–4 years and is clinically characterized by the occur-
rence of myoclonic, atonic, myoclonic-atonic and absence
seizures which are usually preceded by febrile or afebrile
generalized tonic-clonic seizures. The EEG is character-
ized by a normal background with bursts of generalized
2–4 Hz spike or polyspike wave discharges.
LEV efficacy against myoclonic seizures has led to its
off label use in a variety of conditions associated withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hood epilepsies with myoclonic seizures [8-10]. We present
two children diagnosed with epilepsy with myoclonic-
astatic epilepsy (MAE) who experienced a substantial
exacerbation of their myoclonic and atonic seizures fol-
lowing initiation of treatment with LEV and improvement
following discontinuation of this AED. This paradoxical
reaction to LEV in children with MAE was not previously
reported.
Case presentation
Patients identified in this report were enrolled in an on-
going prospective study on children and adults with newly
diagnosed epilepsy. This is a centralized study conducted
at the American University of Beirut Medical Center
(AUBMC) in association with the Lebanese Chapter of
the International League against Epilepsy. One of the prin-
cipal aims of this study is to determine the frequency of
epilepsy syndromes in Lebanon stratified according to age
groups in patients with newly diagnosed epilepsy. Adult
and pediatric neurologists from across Lebanon are refer-
ring patients with suspected newly diagnosed seizure/
epilepsy to the AUBMC where a full history including a
detailed description of the seizures is taken by an epilep-
tologist and physical/neurological examinations are per-
formed. The work-up on each patient includes a 3-hour
sleep deprived video-EEG recording interpreted by two
experienced electroencephalographers along with an epi-
lepsy protocol brain MRI interpreted by a neuroradiologist
blinded to the patient’s history. The results of those tests
are then communicated to the referring physician who de-
cides on whether to initiate treatment (if treatment not
already initiated) and on the choice of AED. A baseline
bone densitometry is performed on patients started on
AED treatment. Patients are then followed up by monthly
phone calls inquiring about medications adverse events,
AED levels and seizure recurrence with follow up visits at
the AUBMC every 3–6 months and repeat video-EEG re-
cording and filling of quality of life questionnaires. This
study is approved by the Institutional review Board of the
AUBMC and all patients enrolled in the study signed an
informed consent form (parental signature for children
and adolescents).
Based on the results of the history, seizure semiology,
physical examination, video/EEG and MRI findings and
follow up (when needed), we stratified patients into idio-
pathic partial, idiopathic generalized, symptomatic par-
tial or symptomatic generalized epilepsies and identified
the electroclinical syndrome, whenever possible, based
on the ILAE classification of epilepsy syndromes [5].
Out of first 307 children and adolescents (less than
18 years of age) with two or more unprovoked seizures en-
rolled in the study, five children (1.6%) were diagnosed
with MAE. There were four boys and one girl, with a meanage of 3.3 years, and a range from 1.9 to 5.4 years. All pa-
tients were initially treated with valproate but failed to
achieve seizure remission. Of the four children subse-
quently treated with add-on LEV, two had no change in
seizure frequency while two others, which are the basis of
this report, had a substantial exacerbation in the frequency
of their myoclonic and atonic seizures following the intro-
duction of this drug.
Case 1
AA is a 3 years 3 months old girl, with a history of new
onset unprovoked nocturnal and diurnal GTCs with no
focal onset for which treatment with valproate was initi-
ated. At her initial evaluation at AUBMC, she had a nor-
mal psychomotor development, normal physical and
neurological examinations, and a history of epilepsy in a
maternal uncle as her only risk factor for epilepsy. A
three-hour sleep deprived EEG revealed a normal awake
background rhythm, and fragments of generalized spike
and wave discharges. Brain MRI was normal except for a
non-specific faint high FLAIR signal in the peritrigonal
white matter. Two months later, the patient started to
develop myoclonic jerks of the upper extremities associ-
ated with hiccup noise followed by head drops and falls
five times daily (the parents described the child as limp
when falling) resulting in multiple head and bodily injur-
ies. A repeat three-hour video/EEG recording revealed
the presence of frequent, 2.5-3.5 Hz generalized, frontally
predominant spike and wave discharges. Treatment with
LEV was initiated at 250 mg BID (31 mg/kg/day). Three
days later, the parents noted that the frequency of the
myoclonic jerks followed by head drop and falls increased
to 10 times daily and then to 15 times daily when the dose
of LEV was further increased to 375 mg BID (47 mg/kg/
day). The dose of LEV was reduced to 250 mg BID with
a rapid reduction of myoclonic-atonic seizures back
to 10 times daily. LEV was tapered and discontinued and
treatment with ethosuximide was initiated with complete
resolution of her seizures and complete normalization of
her EEG.
Case 2
WS is a 22 months old boy, born after an uneventful
pregnancy and with normal psychomotor development,
who presented with a history of 6 unprovoked afebrile
generalized tonic-clonic seizures over a period of 10 days.
The parents also reported noticing multiple daily staring
episodes, each lasting for approximately 10 seconds and
associated with unresponsiveness and blinking. At the
time of his presentation to the AUBMC, treatment with
valproate was already initiated by the referring pediatric
neurologist. His physical and neurological examinations
were normal. There were no risk factors for epilepsy. A
three-hour sleep deprived video/EEG recording revealed
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spike and wave discharges lasting typically between 2
and 5 seconds. Some discharges lasted up to 17 seconds
and were clinically associated with absences. Brain MRI
was normal. Due to the persistence of absence seizures,
add-on treatment with LEV was initiated at 125 mg BID
(21 mg/kg/day) by the referring physician. Two days later,
the child started to experience brief myoclonic jerks, re-
curring in clusters and resulting in brief extension of the
neck. As the dose of LEV was uptitrated to 500 mg/day
(42 mg/kg/day), the parents started noticing frequent
head drops (averaging 3–4 episodes/day) without falls
sometimes preceded by myoclonic jerks of the upper
extremities, but resolution of the staring episodes. A
repeat EEG again showed short bursts of frontally pre-
dominant generalized irregular 2–3 Hz spike and wave ac-
tivity and a myoclonic-astatic seizure was recorded. The
dose of LEV was further increased to 750 mg/day (63 mg/
kg/day) with a substantial increase in the frequency of
the head drops, with an average of 7 such seizures wit-
nessed by the parents on a daily basis. Reduction in
the dose of LEV to 500 mg/day without change in con-
comitant medication resulted in a reduction in the fre-
quency of the head drops to 3 events per day within
24 hours of the reduction in the LEV dose. Subse-
quently, treatment with ethosuximide was initiated and
LEV was tapered and discontinued. This treatment regi-
men resulted in total cessation of seizures and total
normalization of the EEG.
Conclusions
In both children, the introduction of LEV resulted in an
exacerbation of the myoclonic and atonic seizures. Drug
induced exacerbation of seizures are difficult to detect
clinically because of the natural history of epilepsy, with
periods of seizure exacerbations unrelated to a particular
drug regimen. A causal relationship between an AED and
seizure exacerbation is best established when it can be
demonstrated that the introduction of that AED resulted
in increased seizure frequency, its discontinuation resulted
in reduction in seizure frequency, and that a rechallenge
with the AED resulted again in a worsening of seizure fre-
quency. In our patients, although reintroduction of LEV
was not done because of ethical reasons, a causal relation-
ship is strongly suspected not only because of the close
temporal relationship between the introduction of LEV
and worsening seizure frequency but also because of the
dose-related exacerbation in seizure frequency.
In our first case, the child developed myoclonic-atonic
seizures a couple of month after the onset of afebrile
generalized tonic-clonic seizures, a typical sequence for
patients with MAE. A few days after the introduction of
LEV, the daily frequency of myoclonic-atonic seizures
that resulted in falls increased and got proportionatelyworse as the dose of LEV was further increased and im-
proved with dose reduction.
In our second case, the appearance of myoclonic-atonic
seizures shortly after the introduction of LEV could very
well have been a chance association and a reflection of the
natural course of the disease. However, there was again a
very clear exacerbation in the frequency of the mycolonic-
atonic seizures that correlated with progressive increase in
the dose of LEV and a subsequent amelioration with dose
reduction.
In both children, withdrawal of LEV and introduction
of ethosuximide resulted in total seizure remission and
normalization of the EEG. MAE is notoriously a difficult
condition to treat. Although no clinical trial evaluating
the safety and efficacy of AEDs in MAE has been con-
ducted, ethosuximide [11] and valproate [12,13] are usu-
ally advocated as first-line therapy, although the
percentage of children achieving a remission with val-
proate monotherapy is quite low [14]. Other drugs that
have been anecdotally tried include lamotrigine, zonisa-
mide, LEV, and rufinamide [11,15]. The ketogenic diet is
particularly effective for children with MAE, and although
typically used in children refractory to drug treatment,
some have advocated for its use earlier in the clinical
course [16-18].
The efficacy of LEV in MAE was only reported in 9 chil-
dren, with unimpressive results since only one was re-
ported to achieve seizure freedom with a follow-up of only
3 months [8,11,14]. Our data is consistent with those re-
sults since two of the 4 children treated with LEV had no
significant change in seizure frequency while the other
two experienced a significant worsening of their myo-
clonic and atonic seizures, a paradoxical reaction not pre-
viously described for LEV in MAE. There is only one
reported patient with MAE incompletely controlled on
valproate monotherapy who reportedly developed myo-
clonic status epilepticus after replacing valproate with
LEV [19]. This worsening could have been due to the dis-
continuation of valproate, introduction of LEV, natural
history of the illness or any combination of those factors.
A number of AEDs, including carbamazepine, pheny-
toin and vigabatrin should be avoided in MAE because
they frequently result in a significant exacerbation of
seizures [11]. In addition, although the combination of
valproate and lamotrigine is favored by some as a syner-
gistic combination in this condition [20,21], lamotrigine
should be used cautiously in MAE especially in children
with frequent myoclonic seizures since it can worsen this
seizure type [11].
In conclusion, LEV should be used with caution in
children with MAE and an exacerbation of seizure fre-
quency temporally related to the introduction of LEV
should alert the clinician to the possibility of a paradox-
ical seizure exacerbation.
Makke et al. BMC Pediatrics  (2015) 15:6 Page 4 of 4Consent
Written informed consent was obtained from the chil-
dren’s parents for publication of this Case report. A
copy of the written consent is available for review by the
Editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
YM conceived of the study and assisted in the final drafting of the
manuscript. GH assisted in the acquisition of data and the final drafting of
the manuscript. WN assisted in the acquisition of data and the final drafting
of the manuscript. AF assisted in the acquisition of data. AB conceived of the
study and assisted in the acquisition of data and the final drafting of the
manuscript. All authors read and approved the final manuscript.
Funding
Funded in part by grants from the Lebanese National Council for Scientific
Research (Grant number: LCR 114110 522214) and the American University
of Beirut (Grant number: 1131613 52480 115372099990000).
Author details
1Department of Neurology, American University of Beirut Medical Center,
Beirut, Lebanon. 2Department of Pediatric, St George Hospital Medical
University Center, University of Balamand, Beirut, Lebanon.
Received: 5 June 2014 Accepted: 7 January 2015
References
1. Beydoun A, D'Souza J. Treatment of idiopathic generalized epilepsy-a review
of the evidence. Expert Opin Pharmacother. 2012;13:1283–98.
2. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough W,
Schiemann-Delgado J. Levetiracetam for the treatment of idiopathic
generalized epilepsy with myoclonic seizures. Neurology. 2008;70:607–16.
3. Berkovic S, Knowlton R, Leroy R, Schiemann J, Falter U. Placebo-controlled
study of levetiracetam in idiopathic generalized epilepsy. Neurology.
2007;69:1751–60.
4. Doose H, Gerken H, Leonhardt R, Volzke E, Volz C. Centrencephalic
myoclonic-astatic petit mal. Clinical and genetic investigation. Neuropadiatrie.
1970;2:59–78.
5. Commission on Classification and Terminology of the International League
Against Epilepsy. Proposal for revised classification of epilepsies and
epileptic syndromes. Epilepsia. 1989;30:389–99.
6. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W,
et al. Revised terminology and concepts for organization of seizures and
epilepsies: report of the ILAE Commission on Classification and
Terminology, 2005–2009. Epilepsia. 2010;51:676–85.
7. Venot M, Weiss N, Espinoza S, Imbert A, Tadie J-M, Fagon J-Y, et al.
Improvement of early diagnosed post-anoxic myoclonus with levetiracetam.
Intensive Care Med. 2011;37:177–9.
8. Labate A, Colosimo E, Gambardella A, Leggio U, Ambrosio R, Quattrone A.
Levetiracetam in patients with generalised epilepsy and myoclonic seizures:
an open label study. Seizure J Br Epilepsy Assoc. 2006;15:214–8.
9. Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al.
An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy.
Neurology. 2007;69:250–4.
10. Striano P, Sofia V, Capovilla G, Rubboli G, Di Bonaventura C, Coppola A,
et al. A pilot trial of levetiracetam in eyelid myoclonia with absences
(Jeavons syndrome). Epilepsia. 2008;49:425–30.
11. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years
of progress. Dev Med Child Neurol. 2010;52:988–93.
12. Wheless JW, Sankar R. Treatment strategies for myoclonic seizures and
epilepsy syndromes with myoclonic seizures. Epilepsia. 2003;44:27–37.
13. Neubauer BA, Hahn A, Doose H, Tuxhorn I. Myoclonic-astatic epilepsy of
early childhood–definition, course, nosography, and genetics. Adv Neurol.
2005;95:147–55.14. Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy:
clinical experience at the Children's Hospital of Philadelphia. Epilepsia.
2007;48:1703–7.
15. Kluger G, Haberlandt E, Kurlemann G, Ernst J-P, Runge U, Schneider F, et al.
First European long-term experience with the orphan drug rufinamide in
childhood-onset refractory epilepsy. Epilepsy Behav. 2010;17:546–8.
16. Oguni H, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, Shirakawa S, et al.
Treatment and long-term prognosis of myoclonic-astatic epilepsy of early
childhood. Neuropediatrics. 2002;33:122–32.
17. Fejerman N, Caraballo R, Cersosimo R. Ketogenic diet in patients with
Dravet syndrome and myoclonic epilepsies in infancy and early childhood.
Adv Neurol. 2005;95:299–305.
18. Caraballo RH, Cersósimo RO, Sakr D, Cresta A, Escobal N, Fejerman N.
Ketogenic diet in patients with myoclonic-astatic epilepsy. Seizure J Br
Epilepsy Assoc. 2006;4:4.
19. Kröll-Seger J, Mothersill IW, Novak S, Sälke-Kellermann RA, Krämer G.
Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic
epilepsy: a case report. Epileptic Disord. 2006;8:213–8.
20. Dulac O, Kaminska A. Use of lamotrigine in Lennox-Gastaut and related
epilepsy syndromes. J Child Neurol. 1997;12 Suppl 1:S23–8.
21. Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment
with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res.
1998;29:147–54.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
